Abstract:
Background. In recent years, the use of cytokines and various growth factors in the treatment of chronic wounds in pa tients with diabetes mellitus has been of great interest. This manuscript is devoted to this particular problem, which made it
possible to improve the results of treatment.
Material and methods. The results of the treatment of 72 patients with type 2 diabetes mellitus with diabetic foot syn drome are presented, consisting of two groups: the main group (38 patients who, along with the standard treatment of dia betic foot syndrome, underwent local applications with a solution of the immunomodulator Superlymph according to the
generally accepted scheme) and the comparison group (34 patients who used traditional treatment for this pathology). Clin ical, laboratory and instrumental research methods available in clinical settings were used.
Results and conclusions. A change in the local cytokine status in the form of a decrease in anti-inflammatory and an in crease in pro-inflammatory cytokines is characteristic of patients with diabetic foot syndrome. The levels of cytokines of
wound discharge exudate depend on the duration of diabetes mellitus, and the level of glycated haemoglobin and leukocy tosis and do not depend on the form of diabetic foot syndrome. The use of Superlymph in the complex therapy of patients
with diabetic foot syndrome contributes to the normalization of the immune status, which in turn ensures effective healing
of ulcerative foot defects in diabetic foot syndrome.
